Dividend investing has become increasingly popular over time, as generating regular income remains a key focus for investors.
Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...
The US FDA has approved a new drug, Cobenfy, for treating schizophrenia in adults. This is a first new class for medication ...
US regulators have approved a new treatment for schizophrenia, the first of its kind targeting the mental condition in ...
New schizophrenia drug Cobenfy offers hope with fewer side effects targeting symptoms more effectively than traditional ...
The Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), making it the first major ...
The U.S. Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) for the treatment of ...
On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way.
Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in ...
In the year’s fourth-largest deal, Prime Medicine Inc. will collaborate with Bristol Myers Squibb Co. in a research collaboration and license agreement totaling $3.61 billion. The two companies plan ...
The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...
In an effort to expand its cash runway beyond 12 months, Prime Medicines has signed a deal with Bristol Myers Squibb worth a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback